Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population

Psychiatric Genetics

Volumn 14, Issue 3, 2004, Pages 147-150

  Pae, Chi Un ^a   Yu, Hye Sook ^a   Kim, Jung Jin ^a   Kim, Won ^a   Lee, Chang Uk ^a   Lee, Soo Jung ^a   Jun, Tae Youn ^a   Lee, Chul ^a   Paik, In Ho ^a   Serretti, Alessandro ^b  

^a The Catholic University of Korea   (South Korea)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Glutathione S transferase M1 gene (GSTM1) polymorphism; Schizophrenia

Indexed keywords

GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INVOLUNTARY MOVEMENT; KOREA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; AKATHISIA, DRUG-INDUCED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; KOREA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 4644307783     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041444-200409000-00005     Document Type: Article

References (24)

1. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, et al. (2002). The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 26:995-1005.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association.
3. Brockmoller J, Gross D, Kerb R, Drakoulis N, Roots I (1992). Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction. Biochem Pharmacol 43:647-650.
4. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV-Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press.
5. Garver DL, Holcomb J, Mapua FM, Wilson R, Barnes B (2001). Schizophrenia spectrum disorders: an autosomal-wide scan in multiplex pedigrees. Schizophr Res 52:145-160.
6. Gilliland FD, Gauderman WJ, Vora H, Rappaport E, Dubeau L (2002). Effects of glutathione-S-transferase M1, T1, and P1 on childhood lung function growth. Am J Respir Crit Care Med 166:710-716.
7. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H (2003). GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxification enzymes in squamous cell carcinoma of the oral cavity. Oral Dis 9:62-67.
8. Guy W (1976). Abnormal involuntary movement scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, Revised. Washington, DC: Department of Health, Education and Welfare, US DHEW publication; pp. 534-537.
9. Harada S, Fujii C, Hayashi A, Ohkoshi N (2001a). An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 288:887-892.
10. Harada S, Tachikawa H, Kawanishi Y (2001b). Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. Biochem Biophys Res Commun 281:267-271.
11. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (2002). Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58:1-10.
12. Mahadik SP, Evans D, Lal H (2001). Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25:463-493.
13. McLellan RA, Oscarson M, Alexandrie AK, Seidegard J, Evans DA, Rannug A, Ingelman-Sundberg M (1997). Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol Pharmacol 52:958-965.
14. Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, Lee CU (2004). Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 50:54-56.
15. Shaw SH, Kelly M, Smith AB, Shields G, Hopkins PJ, Loftus J, et al. (1998). A genome-wide search for schizophrenia susceptibility genes. Am J Med Genet 81:364-376.
16. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487.
17. Smythies JR (1997). Oxidative reactions and schizophrenia: a review discussion. Schizophr Res 24:357-364.
18. Smythies J (1999). Redox mechanisms at the glutamate synapse and their significance: a review. Eur J Pharmacol 370:1-7.
19. Smythies J (2002). The adrenochrome hypothesis of schizophrenia revisited. Neurotoxicity Res 4:147-150.
20. Pritchard JK, Rosenberg NA (1999). Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65:220-228.
21. Yao JK, Reddy R, van Kammen DP (1998b). Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 80:29-39.
22. Yao JK, Reddy R, McElhinny LG, van Kammen DP (1998a). Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 32:1-8.
23. Yao JK, Reddy R, van Kammen DP (2000). Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 97:137-151.
24. Yao JK, Reddy RD, van Kammen DP (2001). Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287-310.